Abstract
Purpose. To evaluate the effectiveness and safety of three biodegradable terpolymers prepared from L-lactide, trimethylene carbonate, and glycolide (PTLGA) as an aid for trabeculectomy compared with the Ologen (OLO). Methods. Trabeculectomy was carried out on rabbits with implantation made from OLO or three PTLGA terpolymers. Intraocular pressure (IOP) was recorded 1, 2, 3, and 6 months postoperatively and bleb evaluations were performed using ultrasound biomicroscopy (UBM) 3 months after surgery, optical coherence tomography (OCT) every month, and transmission electron microscopy (TEM) six months after surgery followed by histological examination 1, 2, 3, and 6 months postoperatively. Result. IOP was significantly reduced in all groups after surgery. There were no significant differences in the IOL between groups at any time after implantation. There was no significant difference between the groups examined by OCT, UBM, and TEM. Exposure of the implant was observed in one eye from the OLO group and one eye in the P1. Subconjunctiva hyperblastosis was observed in one eye from group P3 and two eyes from the OLO group. Conclusions. Subconjunctival implantation of filtering devices made from PTLGA may present a safe and effective additional surgical tool for the treatment of filtering surgery. Fewer complications were observed in the group with P2 implants compared to other groups.
Highlights
Since trabeculectomy was introduced in 1968, it has been the most common surgery to treat glaucoma [1]
It has been proved that mitomycin C (MMC) raised the success rate of many types of glaucoma filtration surgery [3,4,5], and the use of MMC as a therapeutic agent has been well established as an effective clinical practice at achieving low final intraocular pressures (IOPs)
Severe complications such as leakage, infection, hypotony, and endophthalmitis with complete loss of vision may occur in surgeries with MMC, and surgery still fails in some individuals [6, 7]
Summary
Since trabeculectomy was introduced in 1968, it has been the most common surgery to treat glaucoma [1]. It has been proved that MMC raised the success rate of many types of glaucoma filtration surgery [3,4,5], and the use of MMC as a therapeutic agent has been well established as an effective clinical practice at achieving low final intraocular pressures (IOPs). Severe complications such as leakage, infection, hypotony, and endophthalmitis with complete loss of vision may occur in surgeries with MMC, and surgery still fails in some individuals [6, 7]. Adverse effects of OLO included translocation or exposure of the implant or erosion of the conjunctiva
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
